What to Know About Adjuvant Immunotherapy for Stage II/III Melanoma
Source: Oncology News Central, April 2025
Adjuvant immunotherapy with anti-PD-1 agents improves relapse-free survival in patients with stage II or III melanoma. But does everyone need treatment? Three melanoma experts discuss key data and share how they talk with patients about the decision to undergo adjuvant treatment or opt for observation. They also weigh the importance of different treatment schedules and insights into subcutaneous delivery with nivolumab.